menu
    • menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Metamizole

    Menu

    Metamizole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Takeda Pharmaceutical

    Japan arrow
    ICHH-25
    Not Confirmed

    Takeda Pharmaceutical

    Japan arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Hypera Pharma

    Deal Size : $825.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma

    Details : The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business U...

    Product Name : Neosaldina

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 29, 2021

    Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Hypera Pharma

    Deal Size : $825.0 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Takeda Pharmaceutical

    Japan arrow
    ICHH-25
    Not Confirmed

    Takeda Pharmaceutical

    Japan arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Hypera Pharma

    Deal Size : $825.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Takeda agrees to divest select OTC and Non core assets in Latin America to Hypera Pharma for $825 million USD

    Details : The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    March 02, 2020

    Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Hypera Pharma

    Deal Size : $825.0 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth